Therapeutic Strategies to Overcome ALK Resistance in Cancer

Luc Friboulet, PhD, is ERC Principal Investigator and INSERM team leader at Gustave Roussy cancer campus. He studies the tumor adaptation to kinase inhibitors. Linked to a clinical trial named MATCH-R allowing collection of repeated biopsies in patients treated with ALK, ROS1, RET, EGFR, BRAF, FGFR inhibitors Dr. Friboulet characterizes the resistance mechanisms and establishes new laboratory models.

1. Structure and function of ALK2. ALK rearranged lung cancer: Treatment and outcome3. Systemic treatments other than TKI: reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC4. Management of ALK positive patients with tumors other than lung cancer (ALCL, neuroblastoma, Inflammatory Myofibroblastic Tumor)5. Resistance mechanisms to ALK TKIs in lung cancer: from single to compound mutations, from tissue to liquid biopsy6. Resistance mechanisms to ALK TKI in tumors other than lung cancer7. Therapeutic strategies to overcome ALK resistance in lung cancer8. Novel Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL: use of ACD9. Drug combinations to enhance ALK TKI anti-tumor efficacy in Neuroblastoma10. State of the art and future perspectives